Cargando…
Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
The use of intravenous bisphosphonates (pamidronate or zoledronic acid) is the cornerstone for the management of multiple myeloma-(MM-) related bone disease. However, osteonecrosis of the jaw (ONJ) is a rare, but sometimes difficult to manage, adverse effect of bisphosphonates therapy. A retrospecti...
Autores principales: | Melea, Pelagia I., Melakopoulos, Ioannis, Kastritis, Efstathios, Tesseromatis, Christina, Margaritis, Vasileios, Dimopoulos, Meletios A., Terpos, Evangelos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087254/ https://www.ncbi.nlm.nih.gov/pubmed/25045353 http://dx.doi.org/10.1155/2014/427273 |
Ejemplares similares
-
Conservative Surgical Management of Stage I Bisphosphonate-Related Osteonecrosis of the Jaw
por: Vescovi, Paolo, et al.
Publicado: (2014) -
Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients
por: Walter, Christian, et al.
Publicado: (2010) -
Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone
por: Villa, Alessandro, et al.
Publicado: (2011) -
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013) -
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)